Status:

RECRUITING

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Warm Autoimmune Hemolytic Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Detailed Description

The study consists of a 24-week double-blind, placebo control period, a 144-week open-label extension period and follow-up period of 8 weeks after last study drug administration. Eligible participants...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Participants greater than or equal to (\>=)18 years of age
  • Have been diagnosed with warm autoimmune hemolytic anemia (wAIHA) for at least 3 months, and are currently receiving treatment for wAIHA or have previously received treatment for wAIHA (treatment-naive participants are not eligible)
  • Participants must be able to understand and voluntarily provide written informed consent to participate in the study and comply with all study procedures
  • Exclusion criteria:
  • Participants must not be pregnant or breastfeeding
  • Participants must not have other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate
  • Have been diagnosed with cold antibody autoimmune hemolytic anemia (AIHA), cold agglutinin syndrome, mixed type (that is, warm and cold) AIHA, or paroxysmal cold hemoglobinuria

Exclusion

    Key Trial Info

    Start Date :

    August 15 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 10 2028

    Estimated Enrollment :

    111 Patients enrolled

    Trial Details

    Trial ID

    NCT04119050

    Start Date

    August 15 2019

    End Date

    April 10 2028

    Last Update

    December 19 2025

    Active Locations (171)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 43 (171 locations)

    1

    MemorialCare Medical Group

    Fountain Valley, California, United States, 92708

    2

    University of Southern California

    Los Angeles, California, United States, 90033

    3

    Compassionate Cancer Care

    Riverside, California, United States, 92501

    4

    American Institute of Research

    Whittier, California, United States, 90603